Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Drug Interaction Study in Healthy Subjects to Evaluate the Effects of Multiple Doses of JNJ55308942 on the Cytochrome P450 CYP3A4, CYP2D6 and CYP2C19 Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol

Trial Profile

An Open-Label Drug Interaction Study in Healthy Subjects to Evaluate the Effects of Multiple Doses of JNJ55308942 on the Cytochrome P450 CYP3A4, CYP2D6 and CYP2C19 Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs JNJ-55308942 (Primary) ; Dextromethorphan; Ethinylestradiol/levonorgestrel; Midazolam; Omeprazole
  • Indications Epilepsy; Inflammation; Inflammatory bowel diseases; Mood disorders
  • Focus Pharmacokinetics
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 27 Sep 2018 Status changed from recruiting to completed.
    • 29 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 11 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top